| Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study. |
|
|
| Ann Oncol 34 (Supplement 2, S443-4, 619P) |
|
2023 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.annonc.2023.09.1810 |
|
|
| The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial. |
|
|
| Ann Oncol 34 (Supplement 2, S444-5, 621P) |
|
2023 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.annonc.2023.09.1812 |
|
|
| Zweitlinientherapie mit Nivolumab und bei Nichtansprechen mit Nivolumab+Ipilimumab beim metastasierten urk – Ergebnisse aus TITAN-TCC. |
|
|
| Urologie 61 (Suppl 3): 199 (2022) |
|
2022 |
|
Urothelkarzinom
|
|
|
| doi.org/10.1007/s00120-022-01918-0 |
|
|
| Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma. |
|
|
| J Clin Oncol 40 (19): 2128-37 |
|
2022 |
|
Urothelkarzinom
|
|
|
| ascopubs.org/doi/10.1200/JCO.21.02631 |
|
|
| Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma (TITAN-TCC) |
|
|
| J Clin Oncol 40 (no.6_suppl): 441 |
|
2022 |
|
Urothelkarzinom
|
|
|
| meetings.asco.org/abstracts-presentations/205950 |
|
|
| Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP Registry real-world cohort (AIO-TRK-0315) |
|
|
| Oncol Res Treat 45 (suppl. 3: 5-284): 151 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| www.doi.org/10.1159/000521004 |
|
|
| Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany - AIO-TRK-0315 |
|
|
| Oncol Res Treat 45 (suppl. 3: 5-284): 148 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| www.doi.org/10.1159/000521004 |
|
|
| Nintedanib in combination with nivolumab in pretreated patients with advanced adenocarcinoma of the lung (AIO-TRK-0117 Phase Ib/II trial). |
|
|
| Oncol Res Treat 45 (suppl. 3: 5-284): 163 | poster 1007 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| www.karger.com/Article/Pdf/521004 |
|
|
| Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) – AIO-TRK-0115/PRIMUS. |
|
|
| Oncol Res Treat 45 (suppl. 3: 5-284): 163 | poster 1047 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| www.karger.com/Article/Pdf/521004 |
|
|
| Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP Registry real-world cohort (AIO-TRK-0315). |
|
|
| Oncol Res Treat 45 (suppl. 3: 5-284): 151 | abstract 280 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| www.karger.com/Article/Pdf/521004 |
|
|
